Ergomed plc Total Voting Rights (2368O)
October 01 2019 - 1:00AM
UK Regulatory
TIDMERGO
RNS Number : 2368O
Ergomed plc
01 October 2019
PRESS RELEASE
Total Voting Rights
Guildford, UK - 1 October 2019: In accordance with the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules
("DTRs"), Ergomed plc (the "Company") announces the following
information.
The Company's issued share capital as at 30 September 2019
consisted of 47,164,214 ordinary shares of 1p each, none of which
were held in treasury. Each ordinary share in the capital of the
Company carries one voting right.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company, under the DTRs.
- Ends -
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated
Adviser)
James Black (Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Sue Stuart ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical trials, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services business includes a full range of high-quality
contract research and clinical trial management (CRO) services
under the Ergomed brand together with an industry-leading suite of
specialist pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, and an internationally recognized specialist
expertise in orphan drug development, under the PSR brand. For
further information, visit: http://ergomedplc.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRLMMRTMBMJBPL
(END) Dow Jones Newswires
October 01, 2019 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024